Skip to main content

Medical Oncology

Ausgabe 7/2023

Inhalt (28 Artikel)

Original Paper

Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)

Nikhil Chandnani, Vedika Shrirang Choudhari, Rajat Talukdar, Sudeshna Rakshit, Geetha Shanmugam, Shiuli Guchait, Ishika Gupta, Melvin George, Koustav Sarkar

Original Paper

Isorhamnetin exerts anti-tumor activity in DEN + CCl4-induced HCC mice

Sayanta Sarkar, Abhishek Kumar Das, Semantee Bhattacharya, Ratan Gachhui, Parames C. Sil

Open Access Original Paper

β­caryophyllene oxide induces apoptosis and inhibits proliferation of A549 lung cancer cells

Sameh M. Shabana, Nahla S. Gad, Azza I. Othman, Aly Fahmy Mohamed, Mohamed Amr El-Missiry

Original Paper

Dexamethasone enhances venetoclax-induced apoptosis in acute myeloid leukemia cells

Haixia Wang, Junjie Zhou, Xiaoyu Ma, Changqing Jiao, Enbo Chen, Zhonghui Wu, Yan Zhang, Mengya Pan, Jianling Cui, Chengxin Luan, Jian Ge

Original Paper

A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)

S. Verma, S. Chitikela, V. Singh, S. Khurana, D. Pushpam, D. Jain, S. Kumar, Y. Gupta, P. S. Malik

Open Access Original Paper

Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target

Sourat Darabi, Joanne Xiu, Timothy Samec, Santosh Kesari, Jose Carrillo, Sonikpreet Aulakh, Kyle M. Walsh, Soma Sengupta, Ashley Sumrall, David Spetzler, Michael Glantz, Michael J. Demeure

Original Paper

The crosstalk between ubiquitin-conjugating enzyme E2Q1 and p53 in colorectal cancer: An in vitro analysis

Maryam Rasouli, Sara Khakshournia, Omid Vakili, Sanaz Dastghaib, Atefeh Seghatoleslam, Sayed Mohammad Shafiee

Original Paper

A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer

Hina Qayoom, Mustfa Alkhanani, Abdullah Almilaibary, Suliman A. Alsagaby, Manzoor A. Mir

Open Access Original Paper

Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report

Abhishek Krishna, M. Sathya, S. Mukesh, M. S. Athiyamaan, Sourjya Banerjee, Johan Sunny, Challapalli Srinivas, Dilson Lobo, Bharat Sai Makkapatti, Vaishak Jawahar

Open Access Original Paper

Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)

Abdullah Mahmood Ali, Fatima BenMohamed, Alessandra Decina, Sanjay Mukherjee, Shelley Levi, Laura Nalleli Garrido Castillo, Davide Bréchot, Joseph Jurcic, Azra Raza, Patrizia Paterlini Bréchot

Original Paper

RUNX1/ETO regulates reactive oxygen species (ROS) levels in t(8,21) acute myeloid leukaemia via FLT3 and RAC1

Adam Azlan, Kang Zi Khor, Yaashini Rajasegaran, Aliaa Arina Rosli, Mohamed Saifulaman Mohamed Said, Narazah Mohd Yusoff, Emmanuel Jairaj Moses

Original Paper

Racial and regional disparities in deaths in breast cancer

Akshita Khosla, Devashish Desai, Sachi Singhal, Aanchal Sawhney, Rashmika Potdar

Original Paper

Identification of glycogen phosphorylase L as a potential target for lung cancer

Xin-Ling He, Wen-Yu Lyu, Xin-Yuan Li, Hong Zhao, Lu Qi, Jin-Jian Lu

Perspectives in Oncology

Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy

Simran Deep Kaur, Aman Deep Singh, Deepak N. Kapoor

Review Article

The past, present, and future of immunotherapy for endometrial adenocarcinoma

Anna C. Jones, Karah H. Brown, Tianyun Guan, Luke A. Smith, Cole R. Formslag, Emerson D. Farjado, Qian Bai, Harrison D. Luechtefeld, Mark R. Wakefield, Lijun Dong, Yujiang Fang

Review Article

Implications of IL-21 in solid tumor therapy

Seyed Hossein Abtahi Eivary, Ramiar Kamal Kheder, Soran K. Najmaldin, Nahid Kheradmand, Seyed-Alireza Esmaeili, Jafar Hajavi

Review Article

Recent advancement of HDAC inhibitors against breast cancer

Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, Sangh Partap, Rajshekhar Karpoormath, Brajesh Kumar, Deepak Kumar

Review Article

The future of cancer immunotherapy: DNA vaccines leading the way

Aanshi Pandya, Yesha Shah, Nirjari Kothari, Humzah Postwala, Aayushi Shah, Priyajeet Parekh, Mehul R. Chorawala

Review Article

NK cells direct the perspective approaches to cancer immunotherapy

Abduladheem Turki Jalil, Mohanad Ali Abdulhadi, Farah A. Al-Marzook, Manar Mohammed Hizam, Sada Jasim Abdulameer, Abdul Kareem J. Al-Azzawi, Rahman S. Zabibah, Ali A. Fadhil

Review Article

Current advances in microbial-based cancer therapies

Areej Shahbaz, Tehreem Mahmood, Muhammad Uzair Javed, Bilal Haider Abbasi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.